These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12460076)

  • 21. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 22. A success story with chronic hepatitis C.
    Weekley D; Yuen JC
    J Ark Med Soc; 2005 Dec; 102(6):158-9. PubMed ID: 16381402
    [No Abstract]   [Full Text] [Related]  

  • 23. Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction.
    Keeffe EB
    Semin Liver Dis; 2003; 23 Suppl 1():1-2. PubMed ID: 12934161
    [No Abstract]   [Full Text] [Related]  

  • 24. Loperamide Addiction: Atypical Opioid Use Disorder Treated With Buprenorphine/Naloxone.
    Varghese SP; Kumari P; Wijegunaratne H; Yovankin T; Garlapati V; Koola MM
    Prim Care Companion CNS Disord; 2019 Jul; 21(4):. PubMed ID: 31274259
    [No Abstract]   [Full Text] [Related]  

  • 25. The treatment of viral hepatitis, present and future.
    Rodés J
    J Hepatobiliary Pancreat Surg; 2003; 10(2):163-7. PubMed ID: 14505150
    [No Abstract]   [Full Text] [Related]  

  • 26. [Successful therapy with pegylated interferon alfa-2a. Hepatitis C patients remain virus-free].
    MMW Fortschr Med; 2003 Sep; 145(35-36):56. PubMed ID: 14584218
    [No Abstract]   [Full Text] [Related]  

  • 27. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
    Wedemeyer H; Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of chronic hepatitis C with peginterferon alpha-2a and the factors influencing the effect of this treatment].
    Jin GD; Gong QM; Mao HJ; Xu DZ; Lu ZM
    Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):302-4. PubMed ID: 15850524
    [No Abstract]   [Full Text] [Related]  

  • 29. Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential.
    Sigmon SC; Bigelow GE
    Addiction; 2017 Mar; 112(3):386-387. PubMed ID: 27561982
    [No Abstract]   [Full Text] [Related]  

  • 30. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 31. PEG-IFN, RBV dosing during chronic HCV re-treatment.
    Highleyman L
    IAPAC Mon; 2007 Feb; 13(2):55. PubMed ID: 17948601
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination therapy with telaprevir and pegylated interferon suppresses both wild-type and resistant hepatitis C virus.
    Lang L
    Gastroenterology; 2007 Jan; 132(1):5-6. PubMed ID: 17241851
    [No Abstract]   [Full Text] [Related]  

  • 33. Peginterferon and ribavirin for hepatitis C.
    Duggan AE; Duggan JM
    N Engl J Med; 2007 Mar; 356(12):1269; author reply 1271. PubMed ID: 17377169
    [No Abstract]   [Full Text] [Related]  

  • 34. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is buprenorphine-naloxone ready for prime time in the treatment of opioid addiction in managed care?
    Curtiss FR
    J Manag Care Pharm; 2008 Mar; 14(2):195-7. PubMed ID: 18331121
    [No Abstract]   [Full Text] [Related]  

  • 36. Drugs approved for opiate dependence.
    FDA Consum; 2003; 37(1):6. PubMed ID: 12625293
    [No Abstract]   [Full Text] [Related]  

  • 37. Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis.
    Cua IH; Kwan V; Henriquez M; Kench J; George J
    Gut; 2006 Oct; 55(10):1521-2. PubMed ID: 16966706
    [No Abstract]   [Full Text] [Related]  

  • 38. Indian authority withdraws patent for interferon granted to Roche.
    Kay M
    BMJ; 2012 Nov; 345():e7499. PubMed ID: 23131676
    [No Abstract]   [Full Text] [Related]  

  • 39. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    Taylor LE; Rich JD; Tashima KT
    N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15564553
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment options for opiate addiction.
    J Ky Med Assoc; 2004 May; 102(5):221-4. PubMed ID: 15152448
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.